Citizens Financial Group’s Vertex Pharmaceuticals VRTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $22.2M | Buy |
49,824
+6,421
| +15% | +$2.99M | 0.31% | 68 |
|
|
2025
Q4 | $19.7M | Buy |
43,403
+522
| +1% | +$225K | 0.26% | 76 |
|
|
2025
Q3 | $16.8M | Buy |
42,881
+9,963
| +30% | +$4.16M | 0.23% | 87 |
|
|
2025
Q2 | $14.7M | Buy |
32,918
+10,108
| +44% | +$4.66M | 0.24% | 84 |
|
|
2025
Q1 | $11.1M | Buy |
22,810
+116
| +0.5% | +$54.1K | 0.22% | 93 |
|
|
2024
Q4 | $9.14M | Buy |
22,694
+577
| +3% | +$267K | 0.18% | 100 |
|
|
2024
Q3 | $10.3M | Sell |
22,117
-7,356
| -25% | -$3.53M | 0.21% | 98 |
|
|
2024
Q2 | $13.8M | Buy |
29,473
+99
| +0.3% | +$43K | 0.31% | 68 |
|
|
2024
Q1 | $12.3M | Sell |
29,374
-422
| -1% | -$178K | 0.41% | 48 |
|
|
2023
Q4 | $12.1M | Sell |
29,796
-323
| -1% | -$119K | 0.42% | 50 |
|
|
2023
Q3 | $10.5M | Sell |
30,119
-1,503
| -5% | -$526K | 0.43% | 52 |
|
|
2023
Q2 | $11.1M | Sell |
31,622
-11,557
| -27% | -$3.89M | 0.4% | 54 |
|
|
2023
Q1 | $13.6M | Sell |
43,179
-751
| -2% | -$225K | 0.5% | 42 |
|
|
2022
Q4 | $12.7M | Sell |
43,930
-1,770
| -4% | -$539K | 0.5% | 43 |
|
|
2022
Q3 | $13.2M | Buy |
45,700
+222
| +0.5% | +$63.9K | 0.59% | 37 |
|
|
2022
Q2 | $12.8M | Sell |
45,478
-2,411
| -5% | -$645K | 0.54% | 41 |
|
|
2022
Q1 | $12.5M | Buy |
47,889
+389
| +0.8% | +$92.3K | 0.44% | 55 |
|
|
2021
Q4 | $10.4M | Buy |
47,500
+42,987
| +953% | +$8.36M | 0.35% | 68 |
|
|
2021
Q3 | $819K | Buy |
+4,513
| New | +$881K | 0.03% | 230 |
|
|
2020
Q3 | – | Sell |
-565
| Closed | -$164K | – | 920 |
|
|
2020
Q2 | $164K | Sell |
565
-42
| -7% | -$11.4K | 0.01% | 303 |
|
|
2020
Q1 | $144K | Sell |
607
-58
| -9% | -$13.3K | 0.01% | 297 |
|
|
2019
Q4 | $146K | Buy |
665
+389
| +141% | +$78.7K | 0.01% | 287 |
|
|
2019
Q3 | $47K | Buy |
276
+180
| +188% | +$31.8K | ﹤0.01% | 373 |
|
|
2019
Q2 | $17K | Buy |
96
+40
| +71% | +$6.99K | ﹤0.01% | 476 |
|
|
2019
Q1 | $10K | Sell |
56
-25
| -31% | -$4.62K | ﹤0.01% | 503 |
|
|
2018
Q4 | $13K | Hold |
81
| – | – | ﹤0.01% | 390 |
|
|
2018
Q3 | $16K | Hold |
81
| – | – | ﹤0.01% | 405 |
|
|
2018
Q2 | $14K | Hold |
81
| – | – | ﹤0.01% | 375 |
|
|
2018
Q1 | $13K | Buy |
+81
| New | +$13.2K | ﹤0.01% | 378 |
|
|
2016
Q4 | – | Sell |
-1,157
| Closed | -$101K | – | 679 |
|
|
2016
Q3 | $101K | Sell |
1,157
-32
| -3% | -$3.02K | 0.01% | 294 |
|
|
2016
Q2 | $102K | Buy |
1,189
+253
| +27% | +$21.9K | 0.01% | 295 |
|
|
2016
Q1 | $74K | Buy |
936
+31
| +3% | +$2.8K | 0.01% | 330 |
|
|
2015
Q4 | $114K | Buy |
+905
| New | +$109K | 0.01% | 286 |
|
Other funds holding VRTX
VCM
VPM
Citizens Financial Group's VRTX Position: Q1 2026 in Review
Citizens Financial Group increased its Vertex Pharmaceuticals (VRTX) stake by 15% in Q1 2026, buying an estimated $2.99M and bringing the position to 49,824 shares worth $22.2M. The position accounts for 0.31% of the portfolio, ranked #68.
Citizens Financial Group first reported a position in VRTX in Q4 2015 and has held it in 33 quarters since. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.
- Citizens Financial Group held 49,824 shares of Vertex Pharmaceuticals worth $22.2M as of Q1 2026.
- Citizens Financial Group bought 6,421 Vertex Pharmaceuticals shares in Q1 2026, an estimated $2.99M.
- Vertex Pharmaceuticals made up 0.31% of Citizens Financial Group's portfolio in Q1 2026, its #68 holding.
- Citizens Financial Group first reported a position in Vertex Pharmaceuticals in Q4 2015 and has held it in 33 quarters since.
- 1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.
Based on Citizens Financial Group's 13F filing for Q1 2026, filed 1 May 2026.